Why Parabilis Medicines, Inc.’s (PBLS) Stock Is Up 5.21%
As of Tuesday, August 18, Parabilis Medicines, Inc.’s PBLS share price has surged by 5.21%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Commentary & Analysis
Why Parabilis Medicines, Inc.’s (PBLS) Stock Is Up 6.44%
As of Tuesday, July 21, Parabilis Medicines, Inc.’s PBLS share price has surged by 6.44%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Parabilis Medicines, Inc.’s (PBLS) Stock Is Down 5.92%
As of Monday, July 20, Parabilis Medicines, Inc.’s PBLS share price has dipped by 5.92%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | PBLS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5,104.4 | $289.8 | 67% |
|
| Shares Out (Mil) | 28.9 | 54.4 | 36% |
|
| Institutional Ownership | 99.7% | 92.8% | 92% |
|
| Float (Mil) | 82.1 | 39.7 | 57% |
|
| Beta | na | 0.93 | na |
|
| Avg Daily Volume (000s) | 350 | 524 | 52% |
|
| Price Change (52-week) |
na | 60.8% | na |
|
| Growth | PBLS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.380) | ($2.577) | ($2.187) | |
| Month Ago EPS | ($0.367) | ($1.660) | ($1.900) | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | (83.6%) | (95.7%) | (93.7%) | |
| Financials | PBLS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $37 | 0% |
|
| Net Income (TTM) (Mil) | ($171) | ($43) | 8% |
|
| EPS (TTM) | ($23.446) | ($1.400) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($111) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $1,093 | $2 | 95% |
|
| Long-Term Debt (Q1) (Mil) | $34 | $4 | 36% |
|
| Enterprise Value (Q1) (Mil) | na | $208 | na |
|
| Valuation | PBLS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.87 | 2.86 | 77% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | PBLS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.7% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (29.0%) | (47.6%) | 17% |
|
| ROE | (32.6%) | (54.1%) | 19% |
|
| Liabilities to Assets | 10.9% | 30.2% | 6% |
|
| F-Score | 1 | 2 | na |
|
Parabilis Medicines, Inc. did not pass any screens on 8/19/2026.
